|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the 8 patients (4 men) included in analysis, 4 subgroups of CM were observed, including the BRAF V600E mutation in 1 tumor, NRAS Q61R mutation in 3 tumors, NF1 mutations (Q1188X, R440X, or M1215K+ S15fs) in 3 tumors, and triple-wild type (triple-WT) in 1 tumor.
|
31647501 |
2019 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NGS of the tumor showed an NRAS mutation (c.182A>G:p.Q61R) in 78%, a TP53 mutation (c.856G>A:p.E286K) in 60%, and a TERT gene mutation (1295250C>T) in 28% of the reads.
|
28973495 |
2017 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The primary tumor and all the available metastases exhibited the same molecular oncogenic markers (namely, the RAS mutation p.Q61R and the telomerase promoter mutation C228T).
|
28781658 |
2017 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q</span>61R were SP174 positive.
|
28353383 |
2017 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT<sup> C228T</sup>; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A).
|
27824297 |
2017 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There were no tu</span>mors with overlapping expression of NRAS(Q61R) and BRAF(V600E).
|
26980032 |
2016 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the independent blinded analysis of the remaining cases, the anti-NRAS (Q61R) antibody accurately identified all NRAS Q61R-mutated tumors, and demonstrated 100% sensitivity and specificity.
|
25659223 |
2015 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results show cytoplasmic expression of hnRNP K in human MM surgical specimens, but not in benign nevi, and a quick dose- and time-dependent upregulation in response to IR accompanied by cytoplasmic redistribution of the protein in the IPC-298 cellular tumor model carrying an activating NRAS mutation (p.Q61L).
|
26136337 |
2015 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation specific antibodies against NRAS(Q61R) and BRAF(V600E) proteins could offer additional data on tumor heterogeneity.
|
26204954 |
2015 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Five of the 7 (71%) responders were BRAF(WT), of which 1 carried c-KIT(L576P) and another N-RAS(Q61R) mutation, while only 2 (29%) of the responding tumors were BRAF(V600E/K).
|
22351689 |
2012 |
|
rs11554290
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was detected in 29% of tumours, 41% of CPTC and 16% of FVPTC; N-RAS Q61R mutation was detected in 6% of tumours, 3% of CPTC and 10% of FVPTC.
|
21796448 |
2011 |